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ORIGINAL ARTICLE
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Abstract
Objective: To evaluate whether myo-inositol supplementation may reduce gestational diabetes
mellitus (GDM) rate in overweight women.
Methods: In an open-label, randomized trial, myo-inositol (2 g plus 200mg folic acid twice a day)
or placebo (200 mg folic acid twice a day) was administered from the first trimester to
delivery in pregnant overweight non-obese women (pre-pregnancy body mass index 25
and530 kg/m2). The primary outcome was the incidence of GDM.
Results: From January 2012 to December 2014, 220 pregnant women were randomized at two
Italian University hospitals, 110 to myo-inositol and 110 to placebo. The incidence of GDM was
significantly lower in the myo-inositol group compared to the placebo group (11.6% versus
27.4%, respectively, p¼ 0.004). Myo-inositol treatment was associated with a 67% risk reduction
of developing GDM (OR 0.33; 95% CI 0.15–0.70).
Conclusions: Myo-inositol supplementation, administered since early pregnancy, reduces GDM
incidence in overweight non-obese women.
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Introduction
Gestational diabetes mellitus (GDM) is defined as carbohy-
drate intolerance that begins or is first recognized during
pregnancy [1]. It is associated with an increased risk for the
mother and fetus [2]. From the beginning of 2010, after the
publication of the Hyperglycemia and Adverse Pregnancy
Outcomes (HAPO) study results [2], we follow the recom-
mendations of the International Association of Diabetes in
Pregnancy Study Group (IADPSG) [3] later modified in 2011
by American Diabetes Association (ADA) [4]. However,
these new criteria increased the number of GDM diagnoses to
more than double [5,6], especially in women at risk. In recent
years, our group demonstrated that a diet supplement, an
isomer of inositol, the myo-inositol, has insulin sensitizing
effects [7] and may decrease GDM occurrence in populations
at risk for GDM, like obese women [5] or women with family
history for Diabetes Mellitus type 2 [6]. Myo-inositol is a
cyclitol, normally present in cereals, corn, legumes and meat,
but also synthesized by our body, principally in the liver.
In many countries, myo-inositol is on the market as a
dietary supplement [8], despite its proven pharmacological
effects [9]. BMI ranging 25.1–29.9 is considered a risk
factor predisposing to adverse outcomes in pregnancy [10],
such as GDM and its complications [11]. In this study, we
specifically considered only overweight non-obese women,
with the aim of exploring if also in this category of high risk
women, myo-inositol supplementation might reduce GDM
incidence.
Methods
A randomized, controlled, double-centre, open-label study
was performed involving pregnant outpatients attending the
Units of Gynecology and Obstetrics of two Italian University
Hospitals located in Messina and Modena. The recruitment
started at the beginning of 2012 and lasted 36 months until
reaching the target inclusion of 220 pregnant women. The
inclusion criteria were: (1) pre-pregnancy BMI 425 and
530 kg/m2, (2) first trimester fasting plasma glucose
126 mg/dl and/or random glycemia5200 mg/dl, (3) single
pregnancy and (4) Caucasian ethnicity. Exclusion criteria
were as follow: (1) pre-pregnancy BMI525 and 30 kg/m2,
(2) previous GDM, (3) pre-gestational diabetes, (4) first
trimester glicosuria and (5) treatment with corticosteroids.
The main outcome measure was the occurrence of GDM.
Secondary outcomes were prevalence of fetal macrosomia
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(fetal birth weight 44000 g at delivery), rate of cesarean
section, preterm delivery (537 weeks), Pregnancy Induced
Hypertension (PIH). Cases of shoulder dystocia, neonatal
hypoglycemia and neonates transferred to NICU (Neonatal
Intensive Care Unit) were also recorded. According to ADA
recommendations [4], a diagnosis of GDM was performed at
24th–28th week of gestation with a 75-g 2-h oral glucose
tolerance test (OGTT), cut off values of 92 mg/dl fasting,
 180 mg/dl 1-h post-load and 153 mg/dl 2-h post-load; at
least one of the three values that exceeds or equals the cut off
was enough to diagnose GDM. At the time of the recruitment
(12th–13th week), all the consecutive eligible women who
accepted to participate, after provided written informed
consent, were randomized to placebo or treatment group as
reported below. Randomization list was obtained by using a
computer-generated random allocation with a 1:1 ratio. The
allocations were sealed in numbered white envelopes, which
were kept in the midwifery facility. After the eligibility was
assessed, a midwife opened the next random envelope.
Because of the study design, the gynecologist knew the
group allocation of the patient. Treated group received 2 g
myo-inositol given twice a day plus 200 mg folic acid, whereas
to placebo group only 200 mg folic acid twice a day was
administered. Information on the occurrence of side effects
caused by treatments was collected during follow-up visits. In
particular, the presence of nausea, flatulence, diarrhea,
headache, insomnia, uterine contractions and tiredness was
assessed. At enrollment, fasting glucose and insulin levels
were measured, in order to evaluate the Homeostasis Model
Assessment-Insulin Resistance index (HOMA-IR). HOMA-
IR index was calculated as follows: [(fasting glucose mg/
dl) (fasting insulin mUI/l)/405]. Serum insulin was mea-
sured through an ELISA commercial kit (DRG Diagnostics,
Marburg, Germany), and the concentrations are expressed in
mIU/ml. The protocol was consistent with the principles of the
Declaration of Helsinki, and all participants gave their written
informed consent. The trial is registered as number
NCT01047982. The trial was approved by the Ethical
Committee of Messina University Hospital. Taking into
account that previous trials [5,6] showed a reduction of
67% in the rate of GDM development in the group of
women treated with myo-inositol with respect to placebo, and
considering that the expected rate of GDM in overweight
women is 18% (11), we calculated that 108 women in each
study group would be required to demonstrate a 67% GDM
reduction in the myo-inositol group with a statistical power of
80% (a¼ 0.05). Statistical analysis was carried out with SPSS
statistical package version 17 (SPSS, Chicago, IL). Data are
expressed as mean (SD) for continuous variables and as
percentages for categorical variables. The means of inde-
pendent groups were compared using Student t test after
checking for normal distribution. For comparison of frequen-
cies, Pearson V 2 test was used or, in the case of small
frequencies, the Fisher exact test. A logistic regression
analysis was performed in order to assess odds ratios (ORs)
adjusted for treatment with myo-inositol and recognized risk
factors for GDM, such as pre-pregnancy BMI, parity,
maternal age, family history of DM and weight gain at
OGTT. A value of p 0.05 was considered statistically
significant.
Results
In the myo-inositol group, there was one mid-trimester
miscarriage, five women delivered in other hospitals (thus,
it was impossible to obtain their records) and two women
abandoned the trial, not attending the OGTT evaluation.
Furthermore, there were seven dropouts, principally because
women were negatively influenced by their relatives and
family doctor’s advice, leaving 95 women for the analysis. No
women complained for side effects of the drug. In the placebo
group, there was one mid-trimester miscarriage, two women
abandoned the trial, not attending the OGTT evaluation, and
five delivered in other hospitals, leaving 102 women for the
analysis. The two groups were comparable for maternal age,
pre-pregnancy BMI, percentage of nulliparous women, gly-
cemia, insulinemia and HOMA-IR at first trimester of
pregnancy (Table 1). Women with family history of type 2
DM were more represented in the myo-inositol group
(Table 1). The incidence of GDM, the main outcome measure,
was significantly reduced in the myo-inositol group (n¼ 11,
11.6%) compared with the placebo group (n¼ 28, 27.4%)
(p¼ 0.004). After adjustment for confounding factors such as:
maternal age, pre-pregnancy BMI, weight increase at OGTT,
parity and family history for type 2 DM, only myo-inositol
treatment was associated with a significant reduction of GDM
development risk [OR 0.33 (95% CI 0.15–0.70)]. No signifi-
cant difference in glycemia at each steps of OGTT values
between the two groups was highlighted (Table 2); as well as
in weight gain at the OGTT (Table 3). In the placebo group,
all women with GDM were treated by diet, but there were four
who needed insulin; in the myo-inositol group, only two
women with GDM needed insulin (Table 3). When consider-
ing secondary outcomes there was no difference between
groups in the percentage of cesarean sections (both electives
that emergency, to maternal and/or fetal causes), birth weight,
Table 1. General characteristics of the study groups at the I trimester.
Myo-inositol
(n¼ 95)
Placebo
(n¼ 102) p value
Age (years) 32.1 ± 4.8 32.7 ± 5.3 0.4
Nulliparous (n) 49 (51.6%) 54 (52.9%) 0.8
Pre-pregnancy BMI 26.9 ± 1.3 27.1 ± 1.3 0.4
Family history of DM II (n) 46 (48.4%) 34 (33.3%) 50.001
GA at OGTT (days) 181.2 ± 9.9 180.2 ± 12.2 0.5
Fasting glucose (mg/dl) 81.09 ± 8.03 78.63 ± 6.15 0.3
Fasting insulin (MU/ml) 10.77 ± 7.99 9.96 ± 11.70 0.8
HOMA-IR 2.18 ± 1.69 1.60 ± 1.08 0.2
GA, gestational age; OGTT, oral glucose tolerance test; MU, micro
nternational units/ml; HOMA-IR, homeostasis model assessment of
insulin resistance.
Table 2. OGTT glucose values and incidence of gestational diabetes.
Myo-inositol
(n¼ 95)
Placebo
(n¼ 102) p value
Glycemia T0 (mg/dl) 80.5 ± 7.3 82.5 ± 8.6 0.09
Glycemia T600 (mg/dl) 128.5 ± 30.2 133.4 ± 32.2 0.3
Glycemia T1200 (mg/dl) 106.6 ± 28.0 113.4 ± 27.4 0.07
GDM rate 11.6% (n¼ 11) 27.4% (n¼ 28) 0.004
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gestational age at delivery, macrosomia, PIH, shoulder
dystocia, neonatal hypoglycemia and babies transferred to
NICU (Table 3). At the logistic regression analysis, only the
treatment with myo-inositol (p¼ 0.03) was independently
associated to the onset of GDM.
Discussion
This study shows that myo-inositol intake, since early stages
of pregnancy, in overweight women reduces the incidence of
GDM, confirming the positive effect of this molecule already
highlighted in previous reports [5,6]. Indeed, myo-inositol
supplementation reduced the occurrence of GDM in women at
risk for a positive family history of diabetes mellitus (6%
versus 15.3%) [6]; moreover, the occurrence of GDM in obese
pregnant women was dramatically reduced from 33.6% to
14% in a study recently published by our research group [5].
Several evidences demonstrate that maternal high pre-preg-
nancy BMI has a negative impact on pregnancies outcomes,
with regard to the onset of GDM, hypertensive disorders of
pregnancy and other adverse fetal outcomes [11,12]. This is
probably caused by changes in the impairment in glucose and
lipid metabolism probably already altered in overweight
women. Pregnancy is physiologically characterized by
hyperinsulinemia and insulin resistance [13]. During the
third trimester, insulin sensitivity is reduced up to 50–70%
less than the pre-pregnancy status [14]. Insulin resistance is a
common condition in overweight/obese subjects, because of
the endocrine activity of adipokynes produced by visceral
adipose tissue. It is common knowledge that the increased
visceral adipose tissue regulates the glucose homeostasis, the
energy metabolism, the immune system the coagulation and
the blood pressure [15]. Indeed, abdominal visceral adiposity
seems to have the potential to play a greater role than the
whole body adiposity in high weight-related pregnancy
complications. GDM is almost a worldwide epidemic; it
could be expected that the prevalence of GDM will continue
to undergo an increase because of both the introduction of
new risk factors (often recognized in the general population)
and the lowering of thresholds (just a value outside the cut off
is enough for the GDM diagnosis) requested for the diagnosis.
GDM is associated with increased rates of fetal morbidity
and mortality, both during the pregnancy and in the postnatal
life [16]. Moreover, women with GDM and their infants are at
increased risk for diabetes mellitus and metabolic dysfunction
later in life [17]; thus, strategies to prevent such condition
would be preferable with respect to its treatment. Current
approaches to prevent GDM have focused on lifestyle
interventions such as diet and physical activity [18].
However, the authors of the last Cochrane review concluded
that based on the data currently available, there are no clear
difference in the risk of developing GDM for women
receiving a combined diet and exercise intervention compared
to women receiving no intervention. Recently, some supple-
ments are emerging as additional options; one of these is
myo-inositol, which is an insulin sensitizer substance able to
improve glucose homeostasis. Its mechanism of action is
previously widely described [19]. However, it is remarkable
that in spite of different pre-gestational BMI mean values:
22.8 [5], 33.8 [6] and 26.9 in this study, myo-inositol intake
determines the same effect, with similar reduction in GDM
rate and consequently similar OR (0.35, 0.34, 0.33, respect-
ively). We argue that this data cannot be occasional, whether
the same reduction in GDM rate is obtained from group of
women with so different pre-gestational BMI. These results
are certainly associated with the insulin resistance reduction
induced by myo-inositol, clearly demonstrated in the study on
obese women [6]. Despite the reduction in GDM rate, no
improvement of clinical outcomes, such as macrosomia and
other co-morbidity related to GDM (hypertensive disorders,
shoulder dystocia and pre-term delivery), have been demon-
strated in this study. This could simply depend by the lack of
power respect with previous outcomes. Indeed, the prevalence
of macrosomia or shoulder dystocia is very low. Thus, further
studies are needed with much larger sample of women to
confirm these results and to establish whether a dietary
supplement such as myo-inositol, may reduce not only GDM
rate, but also its related fearful complications.
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